The global demand for Cyclooxygenase 2 Inhibitor Market is presumed to reach the valuation of nearly USD XX MN by 2026 from USD XX MN in 2019 with a CAGR of XX% under the study period of 2020 - 2026.
Cyclooxygenase 2 Inhibitor is a prescription drug used to treat conditions that cause inflammation, mild to moderate pain and fever. The drug acts on the user by blocking the production of cyclooxygenase 2(COX-2), the enzyme which is the major cause for pain, swelling due to inflammation and fever. The COX-2 inhibitors fall under the class of non-steroidal anti-inflammatory drugs but differ from the traditional drugs since they have less harmful side effects on the stomach and intestinal walls. it can be used on patients with arthritis, spondylitis, acute pain and menstrual cramps. It is advised to use these inhibitors after consulting a medic since they can have side effects due to interactions with other drugs.
The rise in the number of patients suffering from various kinds of inflammation will drive the growth of this market. COX 2 inhibitors are the most cost-effective solutions available to handle inflammatory issues and hence the market will see a boost in the coming years. Rise in the rate of inflammation due to changing lifestyles and bad food habits will fuel market growth for COX 2 inhibitors. The market for COX-2 inhibitor will see a peak in the days to come since it can be used to relieve the patient of inflammation caused by COVID -19. This market is faced by a challenge in terms of increased toxicities in gastrointestinal and cardiovascular patients using COX-2 inhibitors.
The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each application/product segment in the global market of cyclooxygenase 2 inhibitor.
The entire cyclooxygenase 2 inhibitor market has been sub-categorized into indication, types, route of administration, end-users, distribution channel. The report provides an analysis of these subsets with respect to the geographical segmentation. This research study will keep marketer informed and helps to identify the target demographics for a product or service.
- Rheumatoid Arthritis
- Menstrual Cramps
By Route of Administration
- Selective Cox 2 Inhibitor
- Non-Selective Cox 2 Inhibitor
By Distribution Channel
- Specialty Clinics
- Hospital Pharmacy
- Retail Pharmacy
This section covers regional segmentation which accentuates on current and future demand for cyclooxygenase 2 inhibitor market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Global Cyclooxygenase 2 Inhibitor Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the cyclooxygenase 2 inhibitor market include Pfizer Inc., Bayer AG, Novartis AG, Sabinsa, Cadila Pharmaceuticals., Mylan N.V., Teva Pharmaceutical Industries Ltd., Alembic Pharmaceuticals Limited, AurobindoPharma, Cipla Inc., Torrent Pharmaceuticals Ltd. and Others. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
This market research report has been produced by gathering information on the basis of primary and secondary research. Secondary research has been done by using various sources which include (but not limited to) Company Websites, Paid Data Sources, Technical Journals, Financial Reports, SEC Filings, and other different industry publications.
If specific information is required which is not currently within the scope of the report, it can be provided as a part of customization.